Biomedical subjects

Yuji Sato

Publications and source records attributed to Yuji Sato.

58 records · Page 4Linked to original sources

PubMed1980

Effects of morphine of human spinal cord and peripheral nervous activities.

The depressant effects of morphine on the evoked electrospinogram (EESG), evoked electromyogram (EEMG) and nerve action potential (NAP) were studied in surgical patients. The EESG was recorded with an epidural electrode in the posterior epidural space in the lumbar enlargement. A clinical dose of morphine (1 mg/kg) depressed the amplitude of all components (P1, N1, P2) of the EESG, elicited by both weak and strong stimuli to the tibial nerve. The depressant effects of morphine were most pronounced on the P2 component of EESG, which is believed to correspond to primary afferent depolarization. The H-relfex was augmented by the drug, while the M-wave and the NAP were unaffected. The changes induced by morphine in both the EESG and the H-reflex were reversed completely, partially or even potentiated by naloxone (0.1 mg/kg). These depressant effects of morphine on the EESG were minimized under nitrous oxide (75%) anaesthesia, indicating the existence of a degree of interaction between these two drugs. Thus, morphine in a clinical anaesthetic dose, affects both spinal cord function and afferent volleys along the roots in normal man.

Action Potentials↗

PubMedDate not supplied

Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials.

The benefit of immunochemotherapy employing a streptococcal preparation, OK-432 (Picibanil), in patients with curatively resected gastric cancer was reassessed by meta-analysis of data from 1,522 patients enrolled in six clinical trials with central randomization. All six trials began between 1985 and 1993, and patients were followed-up for at least 3 years after surgery and enrollment of the last patient. In these trials, standard chemotherapy was compared with the same chemotherapy plus OK-432. The endpoint was overall survival and intent-to-treat analysis was done without patient exclusion. Data were analyzed using the Mantel-Haenszel method. The 3-year survival rate for all eligible patients in the six trials was 67.5% in the immunochemotherapy group versus 62.6% in the chemotherapy group. The 3-year overall survival odds ratio was 0.81 (95% confidence interval: 0.65-0.99). The treatment effect was shown to be statistically significant (p = 0.044). The results of this meta-analysis suggest that immunochemotherapy after surgery with OK-432 can improve the survival of patients with curatively resected gastric cancer.

Antineoplastic Agents↗

PubMedDate not supplied

A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer.

The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or group B. Group A patients received 800 mg/d 5'-DFUR (Furtulon) for 2 years from 2 weeks after the operation. Group B patients received OK-432 plus 5'-DFUR by the same regimen as in group A. This study enrolled 288 patients, and 1 patient with malignant lymphoma was excluded. Among the remaining 287 patients, 143 and 144 were allocated to group A and group B, respectively, and their data were included in statistical analysis. The 5-year survival rates for groups A and B were 62.9% and 63.8%, respectively, showing no significant difference (P = 0.7996).

Adult↗

PubMedDate not supplied

"Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.

BACKGROUND: Based on observations of the clinical course in patients with IgA nephropathy (IgAN), D'Amico et al proposed the concept of the "point of no return (PNR)", after which progression to end-stage renal disease (ESRD) becomes inevitable. They reported that the approximate PNR is serum creatinine (sCr) 3.0 mg/dL. METHODS: To confirm the PNR and to clarify the factors affecting renal function deterioration in IgAN patients, we analyzed the sequential data of those with 1.2 or= 102 mmHg and/or urinary protein (UP) score >or= 2.0 with sCr up to 2.0 mg/dL was significantly poor. Multivariate analysis using the Cox's proportional hazards model, identified only MBP and UP during the course until sCr reached 2.0 mg/dl as independent prognostic factors for ESRD, having hazard ratios of 2.56 (per 10 mmHg; 95% confidence interval (95% CI) 1.08-6.05) and 4.37 (per 0.5 point; 95% CI 1.36-14.1), respectively. CONCLUSIONS: We confirmed PNR as a sCr level of 2.0 mg/dL (equivalent to estimated glomerular filtration rate (GFR) of 30-35 mL/min/1.73m2) during the course of IgAN in Japan. Proper management of both BP and UP until sCr has reached PNR is essential to arrest the progression to ESRD in IgAN.

Adult↗